Korean botulinum toxin brand invests in partner education to drive global adoption.
Daewoong Pharmaceutical has launched a global partner training program for NABOTA, its botulinum toxin A product, signaling confidence in the brand's ability to compete outside South Korea and a commitment to building practitioner competency in markets where NABOTA lacks the installed base of Botox or Dysport.
NABOTA is approved in multiple countries but remains a distant third in most Western markets. Structured training—covering injection technique, unit dosing, patient selection, and adverse-event management—is the playbook for gaining practitioner adoption in competitive territories. Daewoong's investment suggests they are targeting practices in LATAM, parts of Asia-Pacific, and potentially Eastern Europe where price sensitivity and willingness to switch toxin suppliers is higher than in the U.S.
Daewoong invests in global NABOTA training to build practitioner adoption.
For U.S. practice owners, NABOTA remains a niche play, but the training initiative underscores that toxin competition is global and that alternative suppliers will continue investing in market access. The real question is whether Daewoong can secure reimbursement parity or practice-level rebate incentives that make switching from Allergan or Revance economically rational.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
